RxC Expertise
Corporate Strategy
Corporate strategy involves developing and implementing plans to bring greater focus to the organization and its portfolio. Most biopharma companies compete in a few therapeutic areas based on expertise and access to capital. To create sustainable long-term value for shareholders, biopharma companies must pick and choose the areas where they can gain a competitive advantage. An important aspect of corporate strategy in the pharmaceutical industry is the ability to identify and develop new drugs and treatments through a strong R&D program. Additionally, companies must expand their product portfolio through strategic partnerships or acquisitions of other companies or products.
A successful strategic plan allows the organization to achieve its goals (e.g., portfolio alignment, new market entry, acquisitions, and capital investments) while aligning them to stakeholder/shareholder expectations around financials and social responsibility. Business plans allow organizations to translate broader strategic plans into operational plans. These operational plans articulate annual goals, resource allocation, and performance expectations. We have extensive experience developing actionable strategic and operational plans for biopharma companies. An effective biopharma organization must also align structure, processes, and governance.
Key Service Offerings:
Strategic Planning to Target Growth Drivers
Portfolio Strategy & Optimization
Licensing & Acquisition Opportunity Identification
Deal Valuation
New Product Strategy
Biopharma companies embark on a long journey to turn scientific breakthroughs into potential medical treatments to help patients. The actions during this journey must support the vision to make it a reality. A portfolio strategy is necessary when dealing with multiple inline/pipeline assets to ensure optimal positioning and effective resource allocation to drive results. With tight R&D budgets and high failure rates in product development, an objective process is required to assess, prioritize, and allocate resources across R&D initiatives. We have institutionalized the portfolio optimization process using best practices and successfully implemented it at many top biopharma companies.
Therapeutic area and disease strategies are critical for biopharma companies' specialization and long-term value creation. These strategies must be developed using a deeper understanding of clinical, regulatory, medical, and reimbursement pathways. Equally important are the strategic commitment and competency development to win in the chosen area. We collaborate with cross-functional teams to develop these therapeutic area/disease strategies and translate them into actionable strategic roadmaps for execution.
One of the most critical aspects of product development is shaping the drug's target value profile (TVP). A successful TVP development requires understanding future competitive and market access dynamics. The TVP must guide the clinical strategy and support commercial development activities. A solid understanding of a product's potential is critical to make informed investment decisions. We leverage the ProPlan solution to evaluate each product's clinical, regulatory, tech ops, and commercial attractiveness.
Product life cycle strategies range from new indications to label enhancements to end-of-life cycle strategies. The evidence supporting these life cycle programs' is generated via clinical and real-world studies. If successful, LCM strategies can increase the product's lifetime value. Our proprietary solution ProLOGS (Product Product Lifecycle Optimization and Growth Strategy for Maximizing Asset Value) could be leveraged to identify and develop value-creating life cycle solutions.
Key Service Offerings:
Therapeutic Area Strategy
Disease Strategy
Target Product Value Profile
New Product Opportunity Assessment (see ProPlan Solution Offering)
Investment Cases for Go/No-Go Decisions and Deal Support
Product Life Cycle Planning
Commercialization Strategy & Excellence
Commercial Excellence
Once you launch a product, biopharma companies must closely manage performance while objectively evaluating performance issues. We have developed a best-of-breed performance management framework focused on leading and lagging indicators. Biopharma companies could leverage our proprietary "Brand 360 Audit" framework to evaluate key performance drivers and address them timely for course correction.
Key Service Offerings:
Brand 360 Audit
Brand Performance Optimization
Channel Optimization
Process Optimization
Commercialization Strategy
A successful commercialization strategy revolves around creating demand for a given product while ensuring that patients who could benefit from the product gain timely access. The commercial model execution requires alignment of medical, marketing, market access, and supply chain activities. We have assisted several biopharma companies with global and regional commercial strategies—many of the products became quite successful.
Product launches are seminal events for any company in our industry, especially given the arduous development and regulatory process. Biopharma companies must carefully position and differentiate the asset while optimizing market access—careful planning and execution during pre-/peri-/post-launch periods are critical to maximizing the drug's lifetime value. See how we use our proprietary solution ProComS (New Product Commercialization Strategy to Maximize Potential) to help biopharma companies undertake successful commercial planning efforts.
Key Service Offerings:
Strategic Commercial Plan
Launch Sequencing
Brand Strategy
Unmet Patient Needs and Patient Journey
Strategic Segmentation
Channel Strategy
Market Access Strategy
Strategic Roadmap for Launch Planning
Commercial Model Innovation
Case Studies
RxC has worked with clients from around the world to successfully develop and commercialize dozens of products. Below is a representative list of projects to which we have applied our frameworks.
